NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Shenzhen TargetRx

Shenzhen TargetRx

Private
ShenzhenHealthcare & Life Scienceshttps://www.tjrbiosciences.com/

Last Round

Series C

Jan 23, 2025

Total Funding Raised

$106M

Company Overview

Shenzhen TargetRx is a clinical-stage pharmaceutical company that specializes in the research and development of targeted small molecule anti-cancer therapies.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biopharmaceuticaltargeted therapykinase inhibitoroncologyprecision medicinedrug discoveryclinical trialssmall-molecule drugsdrug resistancebiotechpharma licensingALK inhibitorROS1 inhibitorBCR-ABL inhibitordrug pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Shenzhen TargetRx Comparables

Compare Shenzhen TargetRx with similar companies based on industry and business-model similarity.

Shenzhen TargetRx comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Nuvalent, Inc.
78%
Theseus Pharmaceuticals
78%
Ascentage Pharma Group International
76%

Shenzhen TargetRx Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CJan 23, 2025
StrategicSep 7, 2024
Series BJul 5, 2022
StrategicSep 17, 2020
Series AApr 30, 2020
Pre Seed
Jul 25, 2018

Shenzhen TargetRx Investors

Notable investors and investment history

Shenzhen TargetRx investors
InvestorRounds
Oriental Fortune CapitalSeries B, Series A
CDH BaifuSeries B
CCB InternationalSeries B
Shenzhen Capital GroupSeries B, Pre Seed, Series A
Hongtai FundStrategic

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 1, 2025

    Monthly visitors grew 283% MoM, from 313 to 1.2K.

  • Jan 23, 2025

    $50M round completed.

Shenzhen TargetRx Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Shenzhen TargetRx Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Shenzhen TargetRx's valuation, stock price, and market status.

Firmographic Details

HeadquartersShenzhen
Employee Range11
Year Founded2014
Last FundingJan 23, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.